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Abstract
Prostate cancer (PCa) is the second most common cancer, behind skin cancer, among
men, in the United States (Centers for Disease Control and Prevention [CDC], 2019.). PCa is
defined as low-grade or low risk if the neoplasm grows slowly or not at all. According to the
Institute for Quality and Efficiency in Health Care, (2020), to make the conclusion that a PCa is
low-grade, several tests are performed including a prostate specific antigen (PSA) level, a
Gleason score, and a TNM score, which refers to tumor size, lymph node involvement, and
metastasis outside the prostate. Low-grade PCa is further defined by; lack of metastasis outside
the prostate (M0), no lymph node involvement (N0), tumor staging up to T2a, a PSA of less than
10 ng/ml, a Gleason score of less than 6, and no more than two of the 10-12 tissue samples (each
composed of less than 50% cancer cells) of the 10-12 samples taken. Four treatment options exist
for low-grade PCa patients: active surveillance (AS), external beam radiotherapy (EBRT),
brachytherapy, and radical prostatectomy (RP), all of which cause a number of physical and
psychological side effects. The purpose of this scholarly project is to determine if there is a
statistical significance regarding treatment modality chosen and the psychological distress (PD)
experienced by the patient, due to these treatments and their side effects. Additionally, to
determine if early education and close follow up would aid in management of PD. Three
databases were searched: PubMed, CINAHL, and Cochrane Database of Systematic Reviews.
Topics researched included: low-grade prostate cancer, side effects of treatment options and
psychologic distress from the adverse effects of treatment. Research was conducted from June
26, 2019 to January 26, 2020. All works were published within the last 10 years. Limitations and
strengths were considered with each treatment modality. Radical prostatectomy is the most
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effective treatment for low grade PCa. It is also the treatment that is most invasive, causes the
most physical and psychological side effects and has led the medical community to consider low
grade PCa to be over treated. Due to this finding, education regarding an individual’s illness
(grading of the cancer), age, comorbidities, patient’s needs, preference and likely side effects of
treatment must be thoroughly examined, by not only the patient, but with partners and
caregivers.
Keywords: prostate neoplasm, depression, anxiety, radical prostatectomy, brachytherapy,
active surveillance, external beam radiotherapy, psychologic distress, low-grade.
Introduction
In the Unites States, there are approximately 750,000 prostate cancer (PCa) survivors that
suffer from depression (Erim, et al., 2019). Depression and anxiety in low grade PCa can be
linked to a variety of factors, including an individual’s social support system. Historically studies
have found correlations between income, exercise choices or sedentary behaviors and a patient’s
health related quality of life (HRQoL). There have been a handful of studies analyzing the
psychological impacts of the primary treatments for low grade PCa. Currently, the primary
treatments include radical prostatectomy (RP), external beam radiotherapy (EBRT),
brachytherapy (BT), and active surveillance (AS). All these treatments have significant potential
side effects including sexual dysfunction, metastases, and urinary and bowel incontinence
(Sciarra et al.., 2018). Not all low-grade PCa patients are eligible for these treatment options and
unfortunately, one-third of these patients are dissatisfied with the education pertaining to their
treatment options (Lamers, et al.., 2015). Proper information dissemination after diagnosis helps
patients understand PCa, prepares them for treatment, promotes recovery and assists them to
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cope with the disease. The purpose of this study is to compare previous studies findings with
regards to psychological distress (PD) and quality of life (QoL) so that the patient will have
better insight to make their personalized decision for treatment when diagnosed with low-grade
PCa and prepare them for possible outcomes.
Statement of the Problem
Depression occurs in up to 25% of individuals who survive cancer (vs. 5-6% in
noncancer control groups). It is estimated that depression may be even more prevalent in lowgrade PCa survivors due to a decreased likelihood of men reporting depressive symptoms or
seeking psychological help (Erim, et al., 2019). At the time of diagnosis, it is important to supply
these patients with varying points of view, regarding treatments and outcomes, and support them
in their decision making. With each case being unique, it is essential that individuals understand
the long-term outcomes/complications so they can choose the most appropriate treatment choice
for them. With all treatment options, early diagnosis and intervention can reduce overtreatment,
adverse side effects, and psychological distress (Orom, Underwood, and Biddle, 2017). This
scholarly project analyzes the degree of PD (longitudinally through time) and how it correlates
treatment method and degree of physical side effects. This study will also address what effect
early education has for the patient.
Research Question
In low-grade prostate cancer patients, does one treatment modality, active surveillance,
radical prostatectomy, external beam radiation, or brachytherapy, have a higher incidence of
psychological distress than other treatments or the general population? In these patients, does
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early education regarding side effects of treatment help to quantify decision-making and decrease
the psychological distress experienced?
Methods
For this scholarly project, three databases were searched. The databases included
CINAHL, PubMed, and Cochrane Database of Systematic Reviews collected between June 26,
2019 to January 26, 2020. PubMed database was the primary resource for researching depression
and anxiety in low-grade PCa patients from the time of diagnosis and up to seven years post
diagnosis. Subject headings included "prostatic neoplasms"[Mesh Terms] OR "prostatic
neoplasms"[All Fields] OR "prostate neoplasm"[All Fields]) AND (psychological[All Fields]
AND distress[All Fields]) AND ("2009/09/14"[PDAT] : "2019/09/11"[PDAT]) ("Prostatic
Neoplasms/complications"[Mesh] OR "Prostatic Neoplasms/drug therapy"[Mesh] OR "Prostatic
Neoplasms/psychology"[Mesh] OR "Prostatic Neoplasms/radiotherapy"[Mesh] OR "Prostatic
Neoplasms/statistics and numerical data"[Mesh] OR "Prostatic Neoplasms/surgery"[Mesh] OR
"Prostatic Neoplasms/therapy"[Mesh]) AND "Quality of Life/psychology"[Major]. The
CINAHL database subject headings included “Low-grade prostate cancer” [MH], “Treatment”
[MH], “Depression” [MH], and “Anxiety” [MH]. The Cochrane Systematic Review database
was searched with “Low-grade prostate cancer treatment”, “AND” was used between subject
heading to enhance the search. Inclusion criteria for this scholarly project included meta-analysis
and randomized control trials (RCTs). All works were published within the last 10 years and
written in the English language.

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER
Literature Review
Psychologic Distress Prevalence
Three studies were reviewed pertaining to the prevalence of depression and anxiety.
Correlations were made regarding rates of depression and which patient factors were predictive
or protective of depression and anxiety. The timing of depression and anxiety, as a function of
treatment stage was also considered. Rates were compared to those in the general public.
Erim et al. (2019) utilized the data from a population-based cohort of low-grade PCa
survivors from North Carolina that were enrolled from September 2004 to December 2007 and
assessed (n=1031). The study employed the Short Form 12 (SF-12) a validated 12-item selfreported questionnaire that measures generic health-related quality of life. The scale scores range
from 0-100, a higher score indicating better health. The study calls them mental composite scores
(MCS). The SF-12 MC threshold score of 48.9 is 74% sensitive and 83% specific for depression
occurring in the prior 12 months. 48.9 was utilized to create a binary indicator of probable
depression (SF-12 MCS in nondiagnostic), at enrollment and during the 3 indicated annual
follow-up contacts. Predictors the researchers utilized were age at enrollment, race, education
level, rural vs. Urban, marital status, employment annual income, time since diagnosis, stage at
diagnosis, self-reported clinical diagnosis of depression before enrollment, Charlson
Comorbidity Index, social/emotional support, tobacco use, alcohol use, adherence to exercise
recommendations, and treatment decisional regret at follow up. The Generalized estimating
equations (GEEs) with a binomial family, logit link, and independent correlation were used to
evaluate an indicator of probable depression as a function of indicated key explanatory variable
and control covariates. This model was used to predict the average and annual prevalence of
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probable depression in the first 7 years after the cancer diagnosis. 400 participants were lost to
follow-up before the end of the study (no longer answered questionnaires). Participants lost were
most likely to be African American, uninsured, smokers, and low-income earners with a higher
prostate cancer stage at diagnosis.
Erim et al. (2019) found that the average prevalence of apparent depression was 28%
over the study period. The depression was highest in the first 2 years after the cancer diagnosis
(approximately 38%) before significantly declining to 20% in the seventh year. The most
accurate predictors of probable depression were African American race, unemployment, low
income, past depressive episodes, a Charlson Comorbidity Index score of 2 or greater, and
treatment decisional regret. Protective factors were older age at enrollment, length of prostate
cancer survivorship, and adherence to WHO’s exercise recommendations. Treatment decisional
regret affects 4% to 18% of prostate cancer survivors in the short term. The study points to
evidence that decisional regret is likely to occur in prostate cancer survivors who assume a
passive role in cancer treatment decision making.
Limitations of the Erim et al. (2019) study point out that the identification strategy for
depression (SF-12 MCS < 48.90) is imperfect. The false-positives and false-negatives in the data
may bias regression estimates toward the null or increase variances and risks of type II errors in
explanatory variables. Study findings would likely remain solid if a diagnostic tool such as
Patient Health Questionnaire 9 were used to identify depressed study participants (sensitivity,
80%; specificity, 92%). New episodes of probable depression could not be differentiated from
recurrence/relapse, nor could anxiety disorders be separated. The major strength of this study
was that depression history, comorbidities, and low-grade PCa stage were controlled in
regression models.
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Watts et al. (2014) conducted a systematic review and meta-analysis of prevalence rates
of depression and anxiety in low-grade PCa as a function of treatment stage. Watts et al. (2014)
included 27 primary articles (n=4494) in this systematic review. The results of this study
identified pretreatment, on-treatment and post-treatment depression prevalence’s of 17.27%
(95% CI 15.06% to 19.72%), 14.7% (95% CI 11.92% to 17.99%) and 18.44% (95% CI 15.18%
to 22.22%), respectively. Pretreatment, on-treatment and post-treatment anxiety prevalence’s
were 27.04% (95% CI 24.26% to 30.01%), 15.09% (95 % CI 12.15% to 18.6%) and 18.49%
(95% CI 13.81% to24.31%), respectively. These results suggest that men with prostate cancer
have the most psychological distress leading up to the treatment and post-treatment.
Adapted from Watts et al. (2014: BMJ Open, 5(5), e006674-2014-006674.
https://dx.doi.org/10.1136/bmjopen-2014-006674)
Figure 1. Prevalence of depression & anxiety in patients with PCa as a role of treatment stage
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Limitations for this 2014 study include: the inability of this study to differentiate
depression and anxiety prevalence between mild, moderate and metastatic PCa; there is no data
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relating to the patients’ past history of depression or anxiety; this study did not compare
depression and anxiety rates in a cohort to healthy men or men with other cancers; and lastly the
study does not differentiate among types of treatment and their individual depression and anxiety
rates (Watts et al., 2014). It is postulated that the side effects of active surveillance or watchful
waiting as a treatment plan, may increase anxiety. Furthermore, the side effects of radical
prostatectomy may increase depression.
Watts et al. (2015) conducted a quantitative analysis to determine the prevalence of
anxiety and depression in men on active surveillance (AS) for prostate cancer. The researchers
recruited 313 men from a total sample of 426 with a histological diagnosis of PCa that were
currently managed with AS. Biopsy and diagnosis of low-grade PCa had to be made at least 2
months before entry into the study to minimize acute, postdiagnosis mood disturbances.
Additionally, the patient had to be currently managed with AS, be fluent in English, have no
other cancer diagnoses, and no other serious or life-threatening comorbidity that could
significantly impact mood. No restrictions or parameters were put in place in terms of patient age
or time since diagnosis. The results depict that clinical anxiety and depression as determined via
the Hospital Anxiety and Depression Scale (HADS > 8) was 23% (n=73) and 12.5% (n=39),
respectively. This indicates a twofold increase in depression and a threefold increase in anxiety
among AS patients, as compared to men of similar age in the community (British men aged over
65).
With no low-grade PCa cohort of patients receiving radical treatment, Watts et al. (2015)
was unable to determine how the prevalence rates of HADS-based depression and anxiety
observed in the AS patients compare to those seen in patients receiving radical treatment. Also,
anxiety tends to peak among AS patients 3-4 weeks prior to PSA testing and subsides
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substantially, if the subsequent PSA outcome is low. This study had no way to gauge when in the
treatment cycle questionnaires were filled out. This study showed a significant increase of
psychologic distress in PCa patients, which paved the way for further studies to delineate
between the handful of treatment options.
Decisional Self-Efficacy
Decisional self-efficacy, which includes the feeling that a patient has knowledge of all the
factors they may need to make an educated personal decision, play a role in each patient’s
process for their determination of treatment choice. Specifically, patients that have a diagnosis of
low-grade PCa, need to be made aware of the factors which are likely to lead to PD. For a patient
to feel like they have decisional self-efficacy and realistic expectations they must have complete
information from their health care provider, knowledge of their own inclination for emotional
distress, and an accurate understanding of possible side effects. Three articles were chosen to
investigate which patients are less likely to have PD.
Lamers et al. (2016), performed a cross-sectional study where all PCa patients, among the
2011 Eindhoven Cancer Registry (ECR) were eligible for participation (n=999). Sociodemographic data were collected using questionnaires, ECR data was used to obtain clinical
characteristics and further patient information (Gleason score land Tumor-Node-Metastasis
(TNM), and the Self-administered Co-morbidity Questionnaire (SCQ) was used to identify comorbidities. A 25-item questionnaire was used to evaluate the quality of the provider furnished
information (RTC QLQ-INFO-25). For health-related QoL the EORTC QLQ-Core 30
questionnaire was used and for PCa specific questions the EORTC QLQ-PR25 was used. All
scales were linearly converted to a 0-100 scale. Illness perception was evaluated using the Brief
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Illness Perception Questionnaire (B-IPQ), which assesses cognitive and emotional
representations of the illness. A multivariate linear regression analysis showed a significant
positive association between satisfaction with information received and global health (P=0.001),
emotional functioning (P=0.004), social functioning (P=0.027), physical functioning (P=0.002),
and role functioning (P=0.001). Satisfaction was negatively associated with illness perception
subscales on consequences, timeline, personal control, treatment control, illness concern,
coherence and emotional representation. Satisfied patients reported fewer consequence of
disease, illness concern and emotional representation. Those patients had higher personal and
treatment control and coherence.
This Lamer et al. (2016) would be more reliable if the questionnaires were disseminated
at the time of treatment. Due to the timing issue, younger potential respondents were not
reachable. The study is significant in that it shows how educational information regarding a
person’s physical state can minimize the concerns regarding a patient’s future QoL, by keeping
patient expectations realistic.
In the research performed by Orom, Underwood, and Biddle (2017), they investigate
what type of patient may be receiving overtreatment for their low-grade PCa. Overtreatment has
become a considerable matter, especially among those with low-grade PCa. For many with lowgrade PCa, AS could be a viable possibility for disease management. When a patient or
practitioner treats the disease with RP immediately, many judge this to be overtreatment. The
participants in this study were newly diagnosed patients with localized low-grade PCa from two
comprehensive cancer centers and three community facilities between July 2010 and August
2014. The study ended up with 1,531 participants. Emotional distress was measured with the
Distress Thermometer, an analog scale ranging from 0 (no distress) to 10 (extreme distress). The
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researchers then stratified the disease risk by using D’Amico risk score. The score was found by
abstracting clinical stage, pre-treatment biopsy Gleason score, and pre-treatment PSA from
participants’ medical records. Low-risk PCa was defined as PSA< 10 ng/mL, Gleason score < 6,
and American Joint Commission of Cancer Staging (AJCC) less than cT2b. The study used a
multinomial logistic regression to test whether distress at diagnosis or after choosing a treatment
option was associated with greater likelihood of choosing surgery over radiation or active
surveillance. Results found that most participants had low risk PCa (35.7%) or intermediate
(49.1%). Most chose surgery (48.4%), followed by radiation (27.4%) and active surveillance
(24.2%). Distress shortly after diagnosis and after treatment decision making were similar. And
at both times distress was positively correlated with choosing surgery. Distress was not
associated with treatment choice in men with high risk disease. Other determinants of treatment
choice include; those having higher risk disease were more likely to choose surgery and if a
patient had cardiovascular disease (CVD), they were less likely to choose surgery. If the
participant was more educated, they were less likely to choose surgery over the other two
options. Being married was associated with a higher likelihood of choosing surgery and being
older was associated with choosing active surveillance and radiation treatment.
Orom, Underwood, and Biddle (2017) note that this sample is not a representative cross
section of the low-grade PCa population, but one with a high mean socioeconomic status. The
authors also comment that the “Distress Thermometer” is only one measure with the possibility
for error. This study demonstrates that providers should offer early education to newly diagnosed
PCa patients. This education may help with a patient’s anxiety. This study also shows that
increased anxiety leads to increased choice of radical prostatectomy (RP), even when AS may be
feasible.
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Van Stam et al. (2018), performed a prospective, longitudinal cohort study of men with
newly diagnosed localized PCa, (cT1-2 and or Gleason <7, PSA <20 ng/mL), this accounted for
20% of the Dutch localized PCa diagnoses. The goal of this study was to document differences
in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam
radiotherapy (EBRT), brachytherapy (BT), and active surveillance (AS) in a clinician and patient
friendly layout. And to evaluate the extent to which these PROs and other factors are associated
with treatment decision regret. Patients completed questionnaires by email at baseline
(pretreatment) and at 3, 6, and 12 months after treatment or after the start of AS. The ten
outcomes that the patients were asked to report upon were: urinary incontinence, urinary
obstruction and irritation, bowel-related symptoms, sexual dysfunction, hormonal/masculinityrelated symptoms, physical distress, pain, fatigue, emotional distress, and anxiety related to PCa.
Regret about the treatment chosen was assessed with a five-item Decision Regret Scale. The
study found that urinary incontinence was more often reported by patients who receive RP
compared with those under AS. Urinary obstruction and irritation were more frequent in patients
who received EBRT or BT. Sexual dysfunction was common in all active treatment groups, not
AS. Hormonal symptoms were significant in RP and EBRT. During follow-up, emotional
distress was more common in AS patients than among RP patients. Anxiety related to PCa was
not significantly different between treatment groups. All measurable outcomes declined over 12
months, many to the point of being clinically insignificant.
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Figure 2: Association between initial treatment of PCa and patient reported outcomes. Higher
scores indicate more symptoms or more distress (van Stam et al.2018 European Urology
Oncology, https://dx.doi.org/S2588-9311(18)30212-8).
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AS=active surveillance; ASdisc.=changed to active treatment during AS follow-up; RP=radical
prostatectomy; ER=external beam radiotherapy (with or without androgen deprivation therapy;
(ER-)=external beam radiotherapy without androgen deprivation therapy; (ER+) external beam
radiotherapy with androgen deprivation therapy; BT=brachytherapy; The purple shaded areas
indicate the 99% confidence interval of the reference group (AS).
In this 2018 study, the authors stipulated that the subsets of treatment choices were very
small in the EBRT (n=53) and BT (n=45) groups and that the study only followed up to a year,
so longer term information was not available. Though the study covered many PROs, other
factors were likely neglected. The strengths include the large number of participants, across a
diverse area, the researchers utilized a prospective study model, and there were high response
rates. Researchers believe the data found in this study may reflect a clinical scenario. Support in
deciding optimal treatment therapy for each patient will help with regards to outcome and
decisional regret.
Auxiliary Factors
Auxiliary factors including social support, income disparities and exercise vs. sedentary
behavior can affect the health-related quality of life (HRQoL) of patients that have undergone
low-grade PCa treatment. Two of the three articles examined encompassed solely patients that

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

19

had undergone a radical prostatectomy (RP). The third article’s subjects were made up mostly of
low-grade PCa patients, only 4.8% had a Gleason score over 7 (low-grade PCa ≤ Gleason of 6),
but 49.6% of this population also had radical prostatectomy.
Klein et al. (2017), performed a prospective observational study to analyze incomerelated inequality in HRQoL over the course of 12 months after RP using established instruments
to assess general and PCa-specific HRQoL. The participants were requested to fill out a
questionnaire after acute treatment (RP) shortly before discharge form the hospital and at 6
months (t1) as well as 12 months (t2). Patients were excluded if they exceeded the age of 65
years to include as many actively employed individuals as possible, since occupational position
and return to work was a secondary research topic in this project. Income, tumor stage, Gleason
grading, and the method of surgery (open or robot assisted) were assessed. Comorbidities were
self-reported and transformed into the Carlson comorbidity index (CCI). Mental disorders were
recorded at baseline and both follow-ups with the Patient Health Questionnaire-4 (PHQ-4), a
brief self-report questionnaire consisting of a 2-item depression scale (PHQ-2) and a 2-item
anxiety scale (GAD-2). HRQoL was measured at baseline and both follow-ups by the established
cancer-specific and multidimensional EORTC QLQ-C30 core questionnaire. The PCa-specific
module EORTC QLQ-PR25 aims to assess symptoms and functions consisting of five multi-item
scales: urinary symptoms, bowel symptoms, hormonal treatment-related symptoms, sexual
activity, and sexual functioning. The scores of each scale range from 0-100, with higher scores
representing a higher level of functioning/activity as well as a greater degree of symptoms. Four
models were calculated, a basic model (1) including income and the relevant variants age and
partnership status. In model (2) tumor stage, surgical margin status, Gleason score, method of
surgery was introduced. Next comorbidities (CCI) and mental disorders/psychological
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comorbidity were included in model (3). Follow-up treatment factors that could play a role over
the course of one year were introduced in the fourth model. Klein et al. (2017) is quite thorough
and shows highly significant income-related inequalities regarding the majority of HRQol scales.
Less affluent PCa patients reported lower HRQol in terms of global quality of life, all functional
scales and urinary symptoms. After introducing the covariates, some association became
insignificant (physical, cognitive and sexual function), while others only showed reduced
estimates (global quality of life, urinary symptoms, role, emotional and social function). The
mental disorder/psychological comorbidity played a relevant role in the explanation of incomerelated disparities. The unmet need of psychosocial care is common among PCa patients. This
study implies that social inequities have a wide influence on health inequities, so environmental
drivers of these behaviors should be a major concern.
A draw back to the Klein et al. (2017) study included the selective study population of
highly educated Germans, which cannot be representative of the population of treated patients
with prostate cancer in all of Germany, or any other specific country. The strengths include the
prospective design of the study, utilization of linear mixed models, and high response rates.
Interestingly, this is the only study that suggests taking an approach, where the practitioner
considers the natural course of a man’s life, meaning that sexual and urinary dysfunction
becomes more common with age, as does PCa. Hence, to include this knowledge when educating
a patient regarding their disease may make the difference in the PCa affected bodily functions
post-surgery less startling.
Mehnert et al. (2010) conducted a retrospective study to evaluate how low-grade PCa
effects subjective threat, perceived distress, and rates of anxiety, depression and posttraumatic
stress disorder (PTSD) low-grade PCa patients during follow-up care. Patients were recruited
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who had chosen a radical prostatectomy between 1992 and 2003. Patients were scheduled for
follow-up between November 2003 and December 2004, they were tasked to complete a set of
self-report questionnaires. Of the patients evaluated, 76% evaluated their disease as ‘not’ or a
‘little threatening’. The cancer diagnosis itself was most frequently reported as ‘distressing’,
while medical treatment and doctor-patient interaction were most frequently evaluated as ‘most
helpful’. The number of patients reporting increased levels of psychological distress was 16%,
with 6% demonstrating signs of having severe mental health problems. No higher levels of
anxiety and depression were observed in cancer patients compared with age-adjusted normative
comparison groups. Lack of a positive support, detrimental interactions (overprotective behavior,
dismissive, conflictual behavior patterns and pessimism), increased perceived threat of cancer,
diseases stage and age significantly predicted mental health (P< 0.001), whereas the impact of
social support on physical health was rather weak (P = 0.005). Findings emphasize the need for
routine psychosocial screening.
Limitations of the Mehnert et al. (2010) study included that the researchers were unable
to conduct non-responder analyses. It would have been helpful to have information on the quality
of and satisfaction with personal relationships, doctor-patient communication and about patients'
needs for professional psychosocial support. This study reinforces the importance of positive
provider relationships.
Phillips, Stampfer, Chan, Giovannucci, and Kenfield (2015) conducted a prospective
study of 51,529 US male health professionals (lab, radiology, RNs, etc.) who enrolled in 1986,
by completing a questionnaire. This group completes biennial questionnaires. The goal of this
study was to examine relationships between various types and intensities of physical activity,
sedentary lifestyle and PCa-specific HRQoL among prostate cancer survivors and to examine
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potential subgroup effects by demographic and disease characteristics to further refine these
relationships. When PCa is updated into the individual’s file, data on their chosen treatment,
PSA levels, and clinical progression are also included. Expanded Prostate Cancer Index
Composite Short Form (EPIC-26) to assess HRQoL outcomes. Men reported average weekly
time spent during the past year participating in activities, with each activity receiving a metabolic
equivalent task (MET) value. After adjusting for potential confounders, it was determined that
individuals with higher durations of non-vigorous activity and walking activity were associated
with higher vitality/hormonal functioning scores. Survivors who walked > 90 min/week at a
normal pace, or faster, reported higher hormone/vitality scores than men walking < 90 min at an
easy pace (p =0.001). Total activity was associated with higher hormone/vitality functioning in
men who were > 5 years posttreatment, had more advanced disease (Gleason score > 7), and had
> 1 comorbid condition.
Phillips et al. (2015) defined limitations of the study to include its’ inability to fully
determine causality direction because there was no data for HRQoL prior to physical activity
assessment, so the researchers could not rule out the possibility that PCa-specific HRQoL
influences physical activity. Also, the study sample was mostly Caucasian and consisted of
health professionals who may report HRQoL differently. Lastly, physical activity and sedentary
time were measured using self-report, and therefore, there will be some non-differential
measurement error in assessment. Strengths included the ability to control for prediagnosis
actions and to examine whether different types of physical activity differentially affected
HRQoL. By chance, there was enough variability in activity and sedentary time to examine these
differences. According to this study men should include non-vigorous activity to improve their
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HRQoL post PCa treatment. Once again proving that activity improves hormone and vitality
functioning in prostate cancer survivors and the general population.
Primary Treatments Effect on Quality of Life and Psychological Distress
We now compare and analyze the primary treatments of PCa; AS, RP, BT, and EBRT
and these treatment’s effects on the patient’s HRQoL, impact on psychological well-being,
depression, and anxiety. We will also consider the functional effect of the various treatments
(urinary, bowel and sexual dysfunction and/or “bother”) and the idea of overtreatment, and how
the overtreatment of a patient can negatively affect him, possibly causing more harm than good.
Bellardita et al. (2015), performed a systematic review aimed at evaluating the published
evidence on HRQoL and its related psychological dimensions in men undergoing AS, to help
inform clinical practice and treatment decision making. After all exclusions, 10 studies were
included. The psychological dimensions related to HRQoL outcomes were anxiety and
depression, distress, decisional conflict, and mental health. High overall HRQoL scores for AS
patients were reported in 7 out of the 10 studies. No major differences were observed between
the HRQoL scores of those undergoing AS compared to other treatments. Differences in mental
health, anxiety, depression and decisional conflict were not clinically relevant. Though
decisional conflict was less in AS than in RP.
Bellardita et al. (2015) state that some relevant studies may have been omitted from this
review, because of the type of questions were in interview style, instead of questionnaire form.
The interviewers were trying to get pertinent information from cohorts, but because of language,
lack of control group or it was difficult to differentiate between watchful waiting or AS. The
QoL outcomes could not be combined in a meta-analysis because there were no universal

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

24

measures across the 10 studies. Though men that choose AS have less decisional conflict, the
authors postulate that those AS patient’s anxiety may increase over time.
Carter et al. (2015) conducted a systematic review of patients with localized (low-grade)
PCa to determine the impact on psychological wellbeing when treated with AS (non-comparative
studies). These results were then compared to AS with active treatments for the impact on
psychological wellbeing (comparative studies). There were 34 eligible articles were identified (n
= 12,497 individuals). In this study there was little to no differences in psychological distress
comparing AS to the active treatments.
The limitations of this study include that the long-term results are vague for those
practicing AS, because only a few studies follow up with the long-term psychological distress in
this group. Also, the researchers found that they were unable to explain, statistically, men who
switched to an active treatment from AS for psychological reasons. An additional confounding
factor includes the impossibility that all low grade PCa’s are the same, though the staging of the
PCa was similar in all individuals. Carter et al. (2015) takes a broad look at the available studies
with regards to mental health and AS. The information attained in the article could be conveyed
to patients for education, which would help a them feel more confident in choosing AS, if they
had low-grade PCa. AS has specific protocols for regular follow up and AS is not simply
waiting.
Chen et al. (2017) performed an observational study to analyze QoL changes from
baseline (pretreatment) through 2 years after treatment for men who received RP, external beam
radiotherapy (EBRT), or brachytherapy (BT) versus those who pursued AS. The study enrolled
1141 men with localized PCa who had not yet started treatment. Of the 1,141 men participating
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in the study 314 received active surveillance (27.5%), 249 external beam radiotherapy (21.8%),
109 brachytherapy (9.6%), and 469 prostatectomy (41.1%). Participants were
sociodemographically diverse in race, education, and income. Differences in baseline
demographic characteristics and QoL were minimized with propensity weighting. After
propensity weighting, median age was 66 to 67 years across groups, and 77% to 80% of
participants were Caucasian. Patients filled out many questionnaires and variables included in
regression models were race, insurance, marital status, education, income, year of diagnosis, age
at diagnosis and baseline 12-Item Short Form Survey (SF12). Measurements of sexual
dysfunction, urinary obstruction an irritation, urinary incontinence, and bowel problems, were all
considered. Results found that on average, active surveillance may be associated with preserved
QoL, at least in the first 2 years after diagnosis. Radical prostatectomy was associated with
sexual dysfunction and urinary incontinence, whereas radiotherapy was associated with shortterm urinary obstruction and irritation and bowel symptoms.
Chen et al. (2017) explains that the limitations of all observational studies include that
not all patients are starting from the same baseline. Propensity weighting was used to minimize
these differences across groups, but residual confounding is possible and there remained
inconsistent PCa characteristics across groups with favorable characteristics for AS patients and
more negative characteristics for EBRT. Patients were not blinded to treatment received, and
patient expectations regarding outcomes from the treatment they received could affect their
reporting of QoL. Enrollment in the study was only 57%, which could have led to a selection
bias, though other similar studies had similar enrollment. Strengths of this study were that it
included a pretreatment QoL, so there can be precise comparisons. Also, the QoL assessments
were constant, as were the time frames the surveys were completed. This study provides a look at
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some aspects of decision making that are specific to symptoms of various treatments to aid the
patient in making difficult decisions.
Figure 3: Propensity-Weighted PCa Symptom Indices Scores for Urinary, Bowel and Sexual
Symptoms Over Time Across Different Treatment Groups Among Men With Newly Diagnosed
Cancer (Witherite 2020, figure created by data provided by Chen et al., 2017 Jama, 317(11),
1141-1150. https://dx.doi.org/10.1001/jama.2017.1652).
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de Cerqueira, Laranja, Sanches, Monti, and Reis (2015), performed a comprehensive
prospective analysis to understand the deciding factors of treatment choice and to recognize the
three different protocol-based low toxicity methods of treatment; focal cryoablation (FC),
brachytherapy (BT), and AS. Thirty patients were included in the study. This study is
incorporated because it helps to explain what AS treatment entails. De Cerqueira et al. (2015)
points out that AS is a viable treatment option. Many men are not educated regarding the
guidelines of AS, and perceive AS the same as doing nothing, which most consider inherently
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intolerable. Semi-annual PSA measurements and digital rectal examinations as well as annual
magnetic resonance image were offered for consecutive men with very low-risk prostate cancer
(VLRPC) diagnosed by 12 cores sextant biopsy, defined as clinical stage T1c, PSA <0.15
ng/mL, Gleason score < 6, <2 cancer biopsy cores and < 50% involvement of any core with
cancer, who opted for FC, B or AS as equal access protocol-based low-toxicity prostate cancer
managements in a single institution. Exclusion criteria were major life events and morbidity
impacting HRQoL. To avoid potential biases, only those sexually active and able to complete all
questionnaires were included. .Comprehensive, validated self-report questionnaires accessed
patients’ ED and voiding functions and Beck scales measured anxiety, hopelessness and
depression, while SF-36 reflected patients’ HRQoL added to the emotional thermometers
including five visual analogue scales in the form of four predictor domains (distress, anxiety ,
depression, anger) and one outcome domain (need for help), all in the last month. De Cerqueira
et al. (2015) concluded that men that choose AS may have an underreported psychological
burden, though less functional side effects than FC or BT (P < 0.0001).
The limitations of the De Cerqueira et al. (2015) study considering AS should be
counselled that their psychosocial outcomes might not parallel those from patients under lowtoxicity treatment. Psychosocial disparities in outcomes of VLRPC may pose barriers to
widespread application of AS in appropriate patients. include that the study is not useable to
cohorts with higher risk and morbidity characteristics as the series represents a carefully selected
VLRPC patients without co-morbidity (which seems to be consistent with all of these studies,
they were selected because they pertain to low-risk PCa patients).
Löppenberg et al. (2014), assessed whether perioperative complications and functional
outcomes impact quality of life one year after RP. The study included 856 patients who
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underwent open retropubic radical prostatectomy for prostate cancer with minor modifications at
a single academic institution and completed all questionnaires. Quality of life, functional and
oncological outcomes were assessed, preoperatively and 1 year after surgery using the EORTC
QLQ-C30, the IIEF-5 and an institutional questionnaire. Patients without complications were
compared to patients with any, low- or high-grade complications. The overall complication rate
was 27.5 % (235/856). A total of 307 complications were recorded of whom 88.9 % (273/307)
were low grade. In this study, population global health perception did not decline after surgery. It
was found that complications of surgery do not have a profound effect 12 months after surgery.
High grade complications had an impact on emotional function. The most profound impact on
HRQoL was adverse postoperative outcomes such as incontinence, erectile dysfunction,
persistent disease or biochemical recurrence.
Löppenberg et al. (2014) limitations included that there was no way to characterize
adverse events that occurred at home. There could also be a response shift bias, especially
patients who suffered from high-grade complications may perceive their QoL different from
patients who did not experience any complication. One helpful detail of this article is the
definition of the goal of a successful prostatectomy; the trifecta or pentafecta. The Pentafecta
was defined as achievement of Trifecta (negative surgical margin, no postoperative
complications (Clavien-Dindo≥2) and warm ischemia time of ≤ 25 minutes) with addition of
over 90% estimated GFR preservation (eGFR) and no chronic kidney disease (CKD) stage
upgrading at 12 months postoperatively.
Maggi et al. (2019) performed the most recent meta-analysis found on all the search
platforms. The goal of their review was to analyze and compare the current evidence on the
psychological impact of the primary treatments in patients with PCa, such as RP, EBRT, and AS.
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A correlation was also drawn between psychological distress (PD), depression, anxiety and
urinary, sexual, bowel modifications. Also analyzed was the impact of baseline sociodemographic and clinical parameters on psychological aspects, impact of the differing primary
treatments on psychological aspects and correlation among functional and psychological
modifications. All studies were critically evaluated. All questionnaires excepted for the study
were internally recognized. Of 654 articles, 18 were not removed due to duplication or rejection.
The significant findings included the increased PD of patients diagnosed younger, especially
anxiety. Those with less education tended to score higher in depression measures. Urinary
incontinence was the greatest predictor, of the functional symptoms (ED and bowel symptoms),
to foresee psychologic distress. In all active treatments urinary and sexual dysfunction caused
anxiety.
In the 2019, by Maggi et al. the authors state that the quality of studies on these topics is
not high, there are no specific randomized trials and only a few longitudinal comparative studies.
The most positive thing about this study is that it breaks down a handful of studies into
comprehendible bites and gives ideas for future studies. Education regarding the expectations of
incontinence seem to be the most important aspect to share with patients. HADS is used in this
study which makes it more compelling, from a statistical point of view, because it is so widely
utilized. Both graphs below show that although RP starts out with higher anxiety and depression,
RP’s trajectory is heading towards lower anxiety and depression levels.
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Figure 4: Hospital Anxiety and Depression Scale (HADS), Witherite 2020 created by data
provided by Maggi et al. 2019: Andrologia, 51(1) https://dx.doi.org/10.1111/and.13157.
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Matthew et al. (2018), performed a retrospective cross-sectional study to compare the AS
and RP patient experience across the outcomes of psychological distress, affect, lifestyle
disruption, disease specific worry, and treatment decision-making process in men with localized
PCa, in an attempt to further understand psychological wellbeing and the influences on treatment
decision-making in this population. Patients were recruited from a PCa database. Inclusion
criteria were eligibility for AS based on localized PCa (<T3), Gleason score 6 and PSA < 10
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ng/mL with RP or a systematic AS protocol as their primary treatment. Demographic
information was self-reported. The differences between the AS and RP group were examined
using Wilcoxon-Mann Whitney test or T-test for continuous measures and chi-square or Fisher’s
exact test for categorical measures. The total of study packages that were returned and met
eligibility criteria were 206. Of that number, 114 were treated with RP and 92 were managed
with AS. The AS cohort was much older than the RP group at the time of treatment (P= 0.0017).
There was no significant difference in anxiety or depression between the two groups (P=
0.3717). Those that chose RP experienced greater disruption in their intimacy, work, financial
situation, active recreation and health than those that chose AS. Those that chose AS had more
worry about future health and dying than those in the RP group (P= 0.0682). At the time of
treatment selection, those that chose RP were much more fearful of metastasis (P= 0.0002). The
level of the urologist’s impact on treatment decision was appreciably greater in AS patients
compared to men in the RP cohort (P= 0.0022).
Matthew et al. (2018), point out the limitations of the study are a small sample size,
relatively low response rate, single center data, and the absence of data from men undergoing
robotic prostatectomy, which was introduced near the end of the research period. Also, mean
time since diagnosis was greater than 4 years, which can cause recall bias. Lastly, men with
higher anxiety towards PCa chose to undergo RP, reducing the ability to detect a variation in
anxiety levels between groups. The researchers believed that a strength of the study was the
inclusion of researcher designed questions (Appendix 1), that they said provided insight. Which
is what is needed when making a difficult decision. This study helps to clarify education for the
patient, hence aid in decision-making. It also points out how significant the urologist is regarding
decision making.
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Punnen et al. (2013), performed a prospective cohort study that was part of a
longitudinal, comprehensive assessment of patients managed with AS or RP who completed
validated questionnaires reporting levels of depression, anxiety, distress and urinary (UF and
sexual function (SF). The goal of this study was to evaluate the prevalence of depression, anxiety
and distress over time, in men with prostate cancer. First, the mental health of men who were on
AS or underwent a RP, was assessed. Secondly, an evaluation of the impact of depression,
anxiety, and distress on urinary and sexual HRQoL in a subset of men who underwent RP and
had complete follow‐up. These measures were completed at baseline, within 1 year, and between
1 and 3 years from baseline. Mixed model repeated measures analysis was used to examine
associations between mental health at baseline and sexual and urinary outcomes in a subset of
RP patients with complete follow‐up. The subjects were 679 men treated with either RP or AS
returned questionnaires and were included in the study. Baseline prevalence of moderate or
higher levels of depression or anxiety were low (<5%), while levels of mild depression or
anxiety ranged from 3–16% over time. Baseline levels of elevated distress ranged from 8–20%.
There were no significant differences between AS and RP patients in the proportion of men with
elevated levels of depression, anxiety, or distress. Of the 177 men who underwent RP and had
complete follow‐up moderate or higher levels of depression or anxiety appeared to be associated
with post‐treatment SF, elevated levels of distress were correlated with post‐treatment UF.
Punnen et al. (2013) lists the limitations of the study to include that men may be less
likely to admit to mental health issues on an on-line questionnaire. Attrition was also a concern.
The authors mention that there are many variables in a population that distinguish one participant
from another that are impossible to measure. The strengths of this study were a sufficient sample
size, accepted mental health-assessment instruments, and followed the patients longitudinally.
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Sexual and urinary adverse effects are so common, that in addition to patient education, the
researchers stress follow up to treat mental health issues.
Sciarra et al. (2018), conducted a prospective nonrandomized using functional and
psychological questionnaires in PCa patients that utilized either RP, EBRT, or AS. The goal of
this study was to evaluate in a real-life setting the psychological and functional effect of different
treatments of PCa when there was no evidence of disease progression after therapy, during the
first year of follow-up. Inclusion criteria were clinical or pathological staging for localized or
locally advanced PCa (T1,T2,T3, N0, and M0). Exclusion criteria included a history of
neurologic or psychologic diseases or therapies, or other oncologic diseases (n=220). The study
evaluated the cases at baseline, one week before the start of primary treatment, and during the
follow-up at 1-, 3-, 6-, and 12-month interval after therapy. Several significant differences
among the three groups of treatment were found regarding the total score of the functional
questionnaires. With respect to psychological distress, participants that utilized RP showed stable
scores during all the 12 months of follow-up whereas the EBRT group showed a rapid significant
worsening of scores at 1-month interval and persistent also at 6- and 12-month interval.
Participants that chose AS showed a slight and slow worsening scores only at the 12-month
interval (P= 0.0001). PD and depression proved to show a higher association with urinary
symptoms than sexual function worsening whereas anxiety was associated either with urinary
symptoms or sexual function worsening (P= 0.0001).
Sciarra et al. (2018), observe that the limitations of this study are the small number of
cases for the AS group, which can limit statistical significance. Also, patients may be less likely
to show psychological distress symptoms on questionnaires. The main strength of this study was
an age-matched cohort for screening, that did not have PCa. This group was from the same
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ERSPC Rotterdam study and was selected to represent the general population. The follow up
was also a strength, 4-10 years, as was the high percentage response rate and the measurement
tool, the EPIC. This study paints a picture for expectations for three differing treatments, while
utilizing HADS, which is widely used and a positive for comparisons into the future.
Venderbos et al. (2017), performed a cross-sectional study whose goal was to investigate
long-term, 4-10 year, QoL of men with low-risk PCa who were either treated with AS, RP, or
RT. The researchers included an age-matched group of men without PCa as a reference group.
Four groups were sent a one-time QoL-questionnaire; PCa patients (group 1) followed the
structured Prostate cancer Research International Active Surveillance protocol, (group 2)
underwent radical prostatectomy (RP), (group3) who underwent radiotherapy (RT), and (group
4) an age-matched reference group of men without PCa. The QoL-questionnaire addressed
prostate-specific health (EPIC), generic health (SF-12), and anxiety (STAI-6). Statistical
significance (p ≤ 0.05) and clinical relevance (≥0.5 SD) of differences between groups were
assessed. At a mean of 6.6 years of follow-up, AS participants reported better urinary function
[M = 93.0 (SD = 10.6) vs. 80.0 (SD = 19.1), p ≤ 0.001], less urinary incontinence [M = 90.0 (SD
= 14.6) vs. 70.1 (SD = 28.8), p ≤ 0.001], and better sexual function [M = 40.9 (SD = 24.6) vs.
14.8 (17.7), p ≤ 0.001, clinically relevant] than RP participants. Compared to the RT group, the
AS group reported better sexual function [M = 40.9 (SD = 24.6) vs. 25.8 (SD = 25.0), p = 0.069].
The four groups reported similarly low anxiety levels; the number of highly anxious men
(STAI ≥ 44) ranged from 8 to 13%. For all QoL domains, men on AS and men without PCa
reported very similar scores.
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Figure 5. EPIC items on urinary and sexual functioning of relevance for use in daily clinical practice (Venderbos et al. 2017
Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 26(6), 16351645. https://dx.doi.org/10.1007/s11136-017-1507-7

Venderbos et al. (2017), state that the limitations of this study include the low number of
participants in the AS group, when contrasted with the other groups. Researchers, in this study,
again mention that men are less likely to show PD symptoms on a questionnaire. Researchers
believe that the strengths of the study are that it embodies a real-life setting and that it represents
a typical situation of a clinical practice. This study will help with educating patients regarding
expectations. Interestingly, patients in the AS group were not more anxious than those in the RP
or RT group.
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Cognitive Based Therapy and Increase in Antidepressant Use
With changes in the medical field, the rate of PCa diagnoses has increased significantly
and PCa has become, what many call overtreated. Many low-grade PCa neoplasms will grow so
slowly that a patient may not need treatment in their lifetime. For many, the treatment is worse
than the disease. In other themes we have looked at the side effects of low-grade PCa. In theme
five, we look at cognitive based therapy (CBT), mindfulness meditation (MM), and the increase
of antidepressant use in patients that have been treated for PCa. There are many approaches to
battle psychological distress (PD), these have been tested with low-grade PCa.
Victorson et al. (2016), performed a randomized control trial to study the viability and
efficacy of an 8-week mindfulness training program. Men were randomized to either
mindfulness (n = 24) or an attention control arm (n = 19) and completed self‐reported measures
of prostate cancer anxiety, uncertainty intolerance, global quality of life, mindfulness and
posttraumatic growth at baseline, 8 weeks, 6 months and 12 months. The results of MM showed
limited viability, suitability and initial efficacy of using mindfulness training to assist in
decreasing negative AS‐related psychological dysfunction and improve positive ones over time.
The only outcome to demonstrate a substantial increase over the 12-month period was
posttraumatic growth in the mindfulness group, as compared with those in the control group.
Victorson et al. (2016), discloses that the sample size was small, and was analogous in
composition, which does not encompass a less educated or culturally varied groups. The use of a
control group should be considered in future studies. Lastly, this study did not assess patient’s
beliefs and expectations about how effective or ineffective the mindfulness intervention would

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

38

be. It is also mentioned that men are a difficult demographic for psychological interventions,
especially as they age.
Couper et al. (2015), conducted a randomized controlled trial with 62 couples randomly
assigned to the six‐session cognitive existential couple therapy (CECT) program or care as usual.
The goal was to assess efficacy of CECT for relationship function, coping, cancer distress and
mental health in men with low-grade (localized) prostate cancer and their partners. The couple's
relationship function (primary outcome), and coping, cancer distress and mental health
(secondary outcomes) were evaluated at T0 (baseline), T1 (after treatment) and T2 (9 months
from T0). A repeated‐measures analysis of covariance model, which incorporated T0
measurements as a covariate, was used to compare treatment groups at T1 and T2. After CECT,
patients reported significantly greater use of adaptive coping (P = 0.03) and problem‐focused
coping (P = 0.01). These gains were maintained at follow‐up, while relationship cohesion had
improved (P = 0.03), as had relationship function for younger patients (P = 0.01). Younger
partners reported less cancer‐specific distress (P = 0.008), avoidance (P = 0.04), intrusive
thought (P = 0.006), and hyperarousal (P = 0.01). Gains were maintained at follow‐up, while
relationship cohesion (P = 0.007), conflict resolution (P = 0.01) and relational function (P =
0.009) all improved. It was suggested that CECT be disseminated for younger patients regularly,
since they were more open to this type of therapy and they benefited the most.
Couper et al. (2015), share that the main limitations include that the researchers did not
pre-select couples with high distress levels, by randomizing to usual care, there was no active
attention-matched control, and they were unable to comment on how other relationship factors
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such as pretreatment sexual activity or participation in peer support programs may have affected
the outcome. Again, men often deny psychological distress in questionnaires.
Matta et al. (2019), performed a population-based cohort study to research variation and
trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa.
The researchers identified 4952 (41.3%) men who received RP, 4994 (41.0%) who received RT,
and 2136 (17.6%) who were followed with AS, with 1 year of pre-/post index follow-up
available. One year prior to PCa treatment 7.7% of men received an antidepressant prescription,
which increased to 10.5% in the year after treatment. In difference-in-differences (DID) analysis,
adjusted for demographic and health characteristics, men had increased odds of antidepressant
receipt up to 5 year after surgery or RT. Men did not have an increased risk of antidepressant
receipt up to 5 year after AS.
Limitations include the potential for selection bias and misclassification due to the
retrospective design of the study and the use of administrative databases. The strengths of this
study are the length of the study, the large population utilized, and the DID analysis used to
explain control risk of antidepressant receipt. This Matta (2019) study will help educate patients
with regards to expectations and the possibility of future antidepressant use to manage PD post
PCa treatment.
Discussion
This project revealed the numerous important factors to consider when selecting the best
treatment for patients with low-grade prostate cancer. Each treatment has known side effects and
vary in perceived severity based on an individual’s personal experience and what they find most
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important. By covering specific educational and informative topics at the time of diagnosis, a
patient can lower their PD before, during and after their individual course of treatment. Follow
up throughout the course of treatment is imperative to attaining the most positive conclusion.
In low-grade prostate cancer patients, does one treatment modality, active surveillance, radical
prostatectomy, external beam radiation, or brachytherapy, have a higher incidence of
psychological distress than other treatments or the general population.
Would early education regarding side effects of PCa treatments help to quantify decision-making
and decrease the psychological distress experienced?
When analyzing the average prevalence of depression, Erim et al. (2019) found that the
rate was 25% over the seven-year study period. Depression was highest in the first 2 years after
the cancer diagnosis (approximately 38%) before declining to 20% in the seventh year. In the
general population depression is approximately 5-6%, indicating that there is a significant
difference between the two groups. The most accurate predictors of probable depression were
African American race, unemployment, low income, history of a past depressive episode, a
Charlson Comorbidity Index score of 2 or greater, and treatment decisional regret. Treatment
decisional regret affects 4-18% of PCa survivors in the short term. Decisional regret is likely to
occur in prostate cancer patients who assume a passive role in their cancer treatment decision
making. Based on this finding, practitioners should encourage and support patients to make
decisions regarding their treatment plans.
Watts et al.. (2014) conducted a systematic review and meta-analysis of prevalence rates
of depression and anxiety as a function of cancer treatment stage. The results suggest that men
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with prostate cancer have the most PD leading up to the treatment and post-treatment. Watts et
al.. (2014) postulated that the side effects of active surveillance as a treatment plan, may increase
anxiety. This hypothesis led to the Watts et al.. (2015) study of 313 men that were managed with
AS. The results depict that clinical anxiety and depression, as determined via the HADS was
23% and 12.5% respectively. This indicates a twofold increase in depression and threefold
increase in anxiety among AS patients as compared to men of a similar age in the community.
This is a large difference between levels of anxiety and depression. But the comparison is
between those patients utilizing AS, and a non-cancer group. Not a coherent comparison.
When evaluating the research regarding decisional self-efficacy, we looked closely at the
major factors that play a role in each patient’s process for determining which PCa treatment to
pursue. Satisfaction was highest when information about global health, emotional, social,
physical, and role functioning was adequately discussed (Lamars et al. 2017). A negative
association between dissatisfaction with information received and a patient’s timeline, personal
control, treatment control, illness concern, understanding and emotional representation. The
satisfied patients reported fewer consequence of disease, illness concern and emotional
representation and had higher personal and treatment control and understanding. This study
reinforces that knowledge is power. Knowledge regarding a patient’s decisions help to maintain
realistic expectations and improve perceived QoL.
Orom, Underwood, and Biddle (2017) found that a certain type of patient may be
receiving overtreatment for their PCa. This study confirmed that distress was positively
correlated with choosing surgery, more so that when other treatment options were chosen.
Factors that impacted individuals choosing surgical intervention include high risk PCa and being
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married. The researchers postulate that if, as a provider, you can reduce the anxiety a patient is
feeling with proper early education, then the patient may be less likely to choose RP, when AS
may be feasible.
In the study by Van Stam et al. (2018) a comparison was performed between patientreported outcomes (PROs) of various treatments and treatment decision regret. Interestingly, the
treatment that caused the least decision regret was brachytherapy, though brachytherapy was
reported as causing more symptoms and distress than AS in all but two of the 10 PROs. The two
PROs that BT had the least negative effect on were “emotional distress” and “anxiety related to
prostate cancer”, which the researchers weighted more heavily than the urinary, bowel, sexual,
and physical distress symptoms. I find this interesting and am not clear as to why the physical
distress symptoms weren’t more heavily weighted. It seems the physical symptoms, in most of
the literature, have a causal relationship to the emotional distress symptoms.
HRQoL is affected by level of activity, social support, and income disparities. Klein et al.
(2017) found highly significant income-related inequalities regarding the majority of HRQoL
scales. Less affluent PCa patients reported lower HRQoL in terms of global quality of life, all
functional scales and urinary symptoms. Klein et al. (2017) was the only study that suggests the
practitioner educate regarding the natural course of a man’s life, meaning that sexual and urinary
dysfunction become more common with age and if these facts are discussed the decreased bodily
functions post-treatment would be less startling.
Mehnert et al. (2010) found that social support was key in predicted mental health, but
social support did not have a strong correlation with regards to physical health. The researchers
reiterate the importance of positive provider relationships. Phillips et al. (2015) proves in their

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

43

study that activity improves hormone and vitality functioning in prostate cancer survivors and
the general population. Once again, exercise is a healthy habit.
When comparing the many psychological and functional side effects the major PCa
treatments have on patients, we must consider the individuality factor. This factor considers how
differing side effects may cause diverse responses to patients, where one man may not be
bothered by the idea of incontinence, yet the same person cannot imagine going forward having
sexual dysfunction. While the next patient may be completely opposite with their individual
hierarchy of consideration of side effects. The physical side effects, and how they tend to effect
psychological side effects is very pertinent information to share with patients. Patients need this
information so they can adjust expectations and make decisions, with the least amount of
predicted regret as possible, corresponding to their individual hierarchy.
Men who chose AS had less decisional conflict. However, even when there was AS
education for the AS patient and a protocol for them to follow, they also had increased anxiety
over time due to the perceived notion that their cancer was not being treated, or at least not
proactively treated (Bellardita et al, 2015). de Cerqueira et al. (2015) clarify current standard of
practice for AS includes semi-annual PSA measurements, digital rectal examinations as well as
annual magnetic resonance imaging and does not imply by choosing AS that there is not
treatment or that the treatment is simply waiting. de Cerqueira et al. (2015) further concluded
that men that choose AS may have an underreported psychological burden, while simultaneously
having less functional side effects. In the research by Carter et al. (2015), they found that little to
no differences exist in psychological distress comparing AS to the active treatments. Chen et al.
(2017) found that on average, AS may be associated with preserved QoL, at least in the first 2
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years after diagnosis. Punnen et al. (2013), Venderbos et al. (2017), and Sciarra et al. (2018) all
point out that men are less likely to admit to mental health issues, which begs the question, is the
psychological distress experienced more than we are measuring currently?
Both Chen et al. (2017) and Löppenberg et al. (2014) found that the most common side
effects related to RP are sexual dysfunction and urinary incontinence. In two separate studies, it
was found that increased anxiety and depression correlated with post treatment sexual
dysfunction, while elevated reported distress correlated with post treatment urinary incontinence.
Due to the fact that the AS cohort was much older than the RP cohort, at the time of treatment,
the RP group naturally experienced greater disruption in their intimacy, work, financial situation,
active recreation and health than those that chose AS (who were older and may not have work
and likely have a different definition of intimacy) (Matthew et al., 2018). Men with naturally
higher anxiety will most likely choose RP. In another study, Maggi et al. (2019), they found that
urinary incontinence was the greatest predictor of the functional symptoms to foresee
psychologic distress. Sciarra et al. (2018) found that sexual and urinary adverse effects are so
common, that in addition to patient education, the researchers urge follow up to treat mental
health issues.
When reviewing the research regarding PD therapies, the mindfulness training introduced
by Victorson et al. (2016), showed limited viability, suitability and initial efficacy. The
researchers again mentioned that men are a difficult demographic for psychological
interventions, especially as they age. Couper et al. (2015) found that cognitive existential couple
therapy benefited younger couples because they were more open to the program. This study also
mentions that men often deny psychological distress in questionnaires.

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

45

As a practitioner, if you educate patients, manage their expectations and connect with
them, you can relate with the criteria they feel is important (individual hierarchy of treatment
side effects), you will be on your way to a successful patient relationship. Remember to refer
them and their spouse, if applicable, for counselling. Lastly, antidepressant usage is increased by
2.8% in men diagnosed with PCa and should be suggested for more patients due to the finding
that men are less likely to report depression (Matta et al. 2019).
Applicability to Clinical Practice
Due to the increase in early PCa detection, various treatment options, and the treatment
side effects providers must communicate clearly with the patient. The side effects are
considerable and possibly life changing. This scholarly project reveals the many psychological
and physical consequences of low-grade PCa treatments; AS, BT, EBRT, and RP. The patient’s
age, comorbidities, family history, PSA, TNM, and Gleason score must be taken into
consideration. Patient lifestyle and values will help to dictate the most appropriate treatment for
them. Providers should also have a high index of suspicion for depression in all PCa patients,
because men are less apt to report depression and all treatments. During the first two years post
treatment, patients that choose RP and EBRT, should be followed closely for depression. For
those that choose AS, the critical time is two years past post treatment when their anxiety is
likely to increase.
The provider must be well-versed on the treatment options for low-grade PCa, able to
make the safest and most efficacious decision with each patient. The provider will further be able
to consider each patient’s goals and expectations, regarding their disease to personalize treatment
and maximize patient insight to their illness, so that the patient may make their own educated
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choices. A patient well educated and making their own decisions will in turn improve their
HRQoL into the future. This is the preparation that will put them in the driver’s seat.
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Appendix 1
Treatment Decision Factor Questionnaire
1.

2.

3.

Which of the following treatment options were offered to you at diagnosis?
(Circle all that apply)
a. Active Surveillance/ Watchful Waiting (follow up with no active treatment)
b. Surgery (Radical Prostatectomy)
c. External Beam Radiation
d. Brachytherapy
e. Other:
(please specify)
Which treatment option did you choose?
a. Active Surveillance/ Watchful Waiting (follow up with no active treatment
b. Surgery (Radical Prostatectomy)
c. External Beam Radiation
d. Brachytherapy
e. Other:
(please specify)
Indicate how each of the following factors helped you to select the above treatment at the time of the
diagnosis. (Please check one answer for each factor)
1 (not at all)

2

3

4

5 (very much)

Urologist
Other Physician
Friends
Spouse10
Family
TV/newpaper/media
Internet
Other
4.

Please specify how concerned you were regarding the following issues at the time of diagnosis? (Please
check one answer for each factor)
1 (not at all)
2
3
4
5
6
7
8
9
10 (very much)

Fear of cancer
Fear of pain
Concern of treatment side effects
Fear of cancer spread
Erectile dysfunction
Urinary symptoms
What my partner will think
What others will think
5.

How confident were you about your initial treatment choice? (Please circle one letter)
a. I knew right from the beginning, that this was the best option.
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I had some hesitations, but once I made up my mind, I was confident and happy about my treatment
choice.
c. I had some hesitation and could not stop thinking about what would be the best option.
d. I hesitated a lot and had difficulty deciding.
6. How much have you worried about prostate cancer spread or recurrence?
a. Not at all
b. Mild worry
c. Moderate worry
d. Severe worry
7. How much have you worried about your future health since being diagnosed with prostate cancer?
a. More than before treatment
b. Same as before treatment
c. Less than before treatment
8. How much have you worried about dying since being diagnosed with prostate cancer?
a. More than before treatment
b. Same as before treatment
c. Less than before treatment
9. If you have not received active treatment (e.g., surgery, radiation), how much pressure do you feel from
others to undergo active treatment?
a. Not applicable (received active treatment)
b. No pressure
c. Mild pressure
d. Moderate pressure
e. Severe pressure
10. If you received active treatment (e.g., surgery, radiation), how much regret do you experience for
undergoing active treatment?
a. Not applicable (did not receive active treatment)
b. No regret
c. Mild regret
d. Moderate regret
e. Severe regret
11. How much do you worry about burdening friends and family with your prostate cancer diagnosis and
treatment choice?
a. Not at all
b. Mild worry
c. Moderate worry
d. Severe worry

48

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

49

References
Bellardita, L., Valdagni, R., van den Bergh, R., Randsdorp, H., Repetto, C., Venderbos, L. D., . .
. Korfage, I. J. (2015). How does active surveillance for prostate cancer affect quality of
life? A systematic review. European Urology, 67(4), 637-645.
https://dx.doi.org/10.1016/j.eururo.2014.10.028
Bill-Axelson, A., Garmo, H., Holmberg, L., Johansson, J. E., Adami, H. O., Steineck, G., . . .
Rider, J. R. (2013). Long-term distress after radical prostatectomy versus watchful
waiting in prostate cancer: A longitudinal study from the scandinavian prostate cancer
group-4 randomized clinical trial. European Urology, 64(6), 920-928.
https://dx.doi.org/10.1016/j.eururo.2013.02.025
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., . . . Johansson, J.
E. (2014). Radical prostatectomy or watchful waiting in early prostate cancer. The New
England Journal of Medicine, 370(10), 932-942.
https://dx.doi.org/10.1056/NEJMoa1311593
Bill-Axelson, A., Holmberg, L., Garmo, H., Taari, K., Busch, C., Nordling, S., . . . Johansson, J.
E. (2018). Radical prostatectomy or watchful waiting in prostate cancer - 29-year followup. The New England Journal of Medicine, 379(24), 2319-2329.
https://dx.doi.org/10.1056/NEJMoa1807801
Carter, G., Clover, K., Britton, B., Mitchell, A. J., White, M., McLeod, N., . . . Lambert, S. D.
(2015). Wellbeing during active surveillance for localized prostate cancer: A systematic
review of psychological morbidity and quality of life. Cancer Treatment Reviews, 41(1),
46-60. https://dx.doi.org/10.1016/j.ctrv.2014.11.001

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

50

Chen, R. C., Basak, R., Meyer, A. M., Kuo, T. M., Carpenter, W. R., Agans, R. P., . . . Godley,
P. A. (2017). Association between choice of radical prostatectomy, external beam
radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life
among men with localized prostate cancer. Jama, 317(11), 1141-1150.
https://dx.doi.org/10.1001/jama.2017.1652
Couper, J., Collins, A., Bloch, S., Street, A., Duchesne, G., Jones, T., . . . Love, A. (2015).
Cognitive existential couple therapy (CECT) in men and partners facing localised
prostate cancer: A randomised controlled trial. BJU International, 115 Suppl 5, 35-45.
https://dx.doi.org/10.1111/bju.12991
de Cerqueira, M. A., Laranja, W. W., Sanches, B. C., Monti, C. R., & Reis, L. O. (2015). Burden
of focal cryoablation versus brachytherapy versus active surveillance in the treatment of
very low-risk prostate cancer: A preliminary head-to-head comprehensive assessment.
European Journal of Cancer Care, 24(6), 929-937. https://dx.doi.org/10.1111/ecc.12307
Erim, D. O., Bensen, J. T., Mohler, J. L., Fontham, E. T. H., Song, L., Farnan, L., . . . Gaynes, B.
N. (2019). Prevalence and predictors of probable depression in prostate cancer survivors.
Cancer, 125(19), 3418-3427. https://dx.doi.org/10.1002/cncr.32338
Institute for Quality and Efficiency in Health Care. (2020, January 16). What is low-risk prostate
cancer and how is it treated? https://dx.doi.org/www.informedhealth.org/what-is-lowrisk-prostate-cancer-and-how-is-it.2066.en.html?part=behandlung-7i
Klein, J., Ludecke, D., Hofreuter-Gatgens, K., Fisch, M., Graefen, M., & von dem Knesebeck,
O. (2017). Income and health-related quality of life among prostate cancer patients over a
one-year period after radical prostatectomy: A linear mixed model analysis. Quality of

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

51

Life Research: An International Journal of Quality of Life Aspects of Treatment, Care
and Rehabilitation, 26(9), 2363-2373. https://dx.doi.org/10.1007/s11136-017-1582-9
Lamers, R. E., Cuypers, M., Husson, O., de Vries, M., Kil, P. J., Ruud Bosch, J. L., & van de
Poll-Franse, L. V. (2016). Patients are dissatisfied with information provision: Perceived
information provision and quality of life in prostate cancer patients. Psycho-Oncology,
25(6), 633-640. https://dx.doi.org/10.1002/pon.3981
Löppenberg, B., von Bodman, C., Brock, M., Roghmann, F., Noldus, J., & Palisaar, R. J. (2014).
Effect of perioperative complications and functional outcomes on health-related quality
of life after radical prostatectomy. Quality of Life Research: An International Journal of
Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(10), 2743-2756.
https://dx.doi.org/10.1007/s11136-014-0729-1
Maggi, M., Gentilucci, A., Salciccia, S., Gatto, A., Gentile, V., Colarieti, A., . . . Sciarra, A.
(2019). Psychological impact of different primary treatments for prostate cancer: A
critical analysis. Andrologia, 51(1) https://dx.doi.org/10.1111/and.13157
Matta, R., Wallis, C. J. D., Goldenberg, M. G., Hird, A. E., Klaassen, Z., Kulkarni, G., . . . Nam,
R. K. (2019). Variation and trends in antidepressant prescribing for men undergoing
treatment for nonmetastatic prostate cancer: A population-based cohort study. European
Urology, 75(1), 3-7. https://dx.doi.org/S0302-2838(18)30630-4
Matthew, A. G., Raz, O., Currie, K. L., Louis, A. S., Jiang, H., Davidson, T., . . . Trachtenberg, J.
(2018). Psychological distress and lifestyle disruption in low-risk prostate cancer
patients: Comparison between active surveillance and radical prostatectomy. Journal of
Psychosocial Oncology, 36(2), 159-174.
https://dx.doi.org/10.1080/07347332.2017.1342733

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

52

Meissner, V. H., Herkommer, K., Marten-Mittag, B., Gschwend, J. E., & Dinkel, A. (2017).
Prostate cancer-related anxiety in long-term survivors after radical prostatectomy.
Journal of Cancer Survivorship: Research and Practice, 11(6), 800-807.
https://dx.doi.org/10.1007/s11764-017-0619-y
Mehnert, A., Lehmann, C., Graefen, M., Huland, H., & Koch, U. (2010). Depression, anxiety,
post-traumatic stress disorder and health-related quality of life and its association with
social support in ambulatory prostate cancer patients. European Journal of Cancer Care,
19(6), 736-745. https://dx.doi.org/10.1111/j.1365-2354.2009.01117.x
Orom, H., Underwood, W.,3rd, & Biddle, C. (2017). Emotional distress increases the likelihood
of undergoing surgery among men with localized prostate cancer. The Journal of
Urology, 197(2), 350-355. https://dx.doi.org/S0022-5347(16)30973-9
Phillips, S. M., Stampfer, M. J., Chan, J. M., Giovannucci, E. L., & Kenfield, S. A. (2015).
Physical activity, sedentary behavior, and health-related quality of life in prostate cancer
survivors in the health professionals follow-up study. Journal of Cancer Survivorship:
Research and Practice, 9(3), 500-511. https://dx.doi.org/10.1007/s11764-015-0426-2
Punnen, S., Cowan, J. E., Dunn, L. B., Shumay, D. M., Carroll, P. R., & Cooperberg, M. R.
(2013). A longitudinal study of anxiety, depression and distress as predictors of sexual
and urinary quality of life in men with prostate cancer. BJU International, 112(2), E6775. https://dx.doi.org/10.1111/bju.12209
Sciarra, A., Gentilucci, A., Salciccia, S., Von Heland, M., Ricciuti, G. P., Marzio, V., . . . Maggi,
M. (2018). Psychological and functional effect of different primary treatments for
prostate cancer: A comparative prospective analysis. Urologic Oncology, 36(7), 340.e7340.e21. https://dx.doi.org/S1078-1439(18)30121-2

DECISION MAKING FOR LOW-GRADE PROSTATE CANCER

53

van Stam, M. A., Aaronson, N. K., Bosch, J. L. H. R., Kieffer, J. M., van der Voort van
Zyp,J.R.N., Tillier, C. N., . . . van der Poel, H. G. (2018). Patient-reported outcomes
following treatment of localised prostate cancer and their association with regret about
treatment choices. European Urology Oncology, https://dx.doi.org/S25889311(18)30212-8
Venderbos, L. D. F., Aluwini, S., Roobol, M. J., Bokhorst, L. P., Oomens, E. H. G. M., Bangma,
C. H., & Korfage, I. J. (2017). Long-term follow-up after active surveillance or curative
treatment: Quality-of-life outcomes of men with low-risk prostate cancer. Quality of Life
Research: An International Journal of Quality of Life Aspects of Treatment, Care and
Rehabilitation, 26(6), 1635-1645. https://dx.doi.org/10.1007/s11136-017-1507-7
Victorson, D., Hankin, V., Burns, J., Weiland, R., Maletich, C., Sufrin, N., … Brendler, C.
(2016). Feasibility, acceptability and preliminary psychological benefits of mindfulness
meditation training in a sample of men diagnosed with prostate cancer on active
surveillance: results from a randomized controlled pilot trial. Psycho-Oncology, 26(8),
1155–1163. https://dx.doi.org/10.1002/pon.4135
Watts, S., Leydon, G., Birch, B., Prescott, P., Lai, L., Eardley, S., & Lewith, G. (2014).
Depression and anxiety in prostate cancer: A systematic review and meta-analysis of
prevalence rates. BMJ Open, 4(3), e003901-2013-003901.
https://dx.doi.org/10.1136/bmjopen-2013-003901
Watts, S., Leydon, G., Eyles, C., Moore, C. M., Richardson, A., Birch, B., . . . Lewith, G. (2015).
A quantitative analysis of the prevalence of clinical depression and anxiety in patients
with prostate cancer undergoing active surveillance. BMJ Open, 5(5), e006674-2014006674. https://dx.doi.org/10.1136/bmjopen-2014-006674

